Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) said on Wednesday that it has entered into a new contract with an undisclosed APAC country for the supply of 350,000 doses of its non-replicating JYNNEOS smallpox/monkeypox vaccine.

Deliveries and all revenues under this contract will occur in 2023.

This latest order follows an initial order with the same country for supply in 2022.

Paul Chaplin, president and CEO of Bavarian Nordic, said in a statement: "While governments and health authorities around the world are busy fighting the current monkeypox outbreak we applaud those governments thinking beyond the current situation and building stockpiles to secure future preparedness and we are proud to assist our customers in both efforts."

With this order, together with previously announced orders from the US, Canada and other countries, Bavarian Nordic said that it now has significant orders of smallpox/monkeypox vaccines.